Skip to main content

Table 4 The dose responses to aspirin among the HCV patients

From: Aspirin decreases hepatocellular carcinoma risk in hepatitis C virus carriers: a nationwide cohort study

Duration of aspirin use

Event no.

Crude

Adjusted

(n = 278)

HR

(95% CI)

p value

HR

(95% CI)

p value

Non-user

147

1

reference

 

1

reference

 

< 1 year

93

0.74

(0.57–0.96)

0.02

0.63

(0.48–0.83)

< 0.001

1–2 years

12

0.52

(0.29–0.93)

0.03

0.33

(0.18–0.61)

< 0.001

2–3 years

11

0.94

(0.51–1.73)

0.84

0.6

(0.32–1.13)

0.11

≥3 years

15

0.8

(0.47–1.37)

0.42

0.45

(0.26–0.79)

0.005

  1. Abbreviations: HR Hazard ratio, CI Confidence interval, NSAIDs Non-steroidal anti-inflammatory drugs
  2. Adjusted HR: adjusted for gender, age, hypertension, diabetes mellitus, moderate or severe liver disease, myocardial infarction, congestive heart failure, ischemic stroke, anti-hypertension agents, hypoglycemic agents, coumadin and heparin, other antithrombotic agents and NSAIDs in Cox proportional hazards regression